Noninfectious pulmonary complications of HIV/AIDS

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Purpose of review: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era. Recent findings: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients. This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients. The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients. Concurrent uge of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma. For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment. Summary: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies. Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer. The full impact of HAART on HIV pulmonary hypertension remains to be determined.

Original languageEnglish (US)
Pages (from-to)208-212
Number of pages5
JournalCurrent Opinion in Pulmonary Medicine
Volume11
Issue number3
DOIs
StatePublished - May 2005

Fingerprint

Acquired Immunodeficiency Syndrome
Highly Active Antiretroviral Therapy
HIV
Lung
AIDS-Related Lymphoma
Pulmonary Hypertension
Kaposi's Sarcoma
Lung Neoplasms
Neoplasms
Survival
Incidence
Immunosuppression
Antihypertensive Agents
Morbidity
Drug Therapy
Mortality
Therapeutics
Population

Keywords

  • Cancer
  • Complications
  • HIV/AIDS
  • Highly active antiretroviral therapy
  • Pulmonary pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Noninfectious pulmonary complications of HIV/AIDS. / Kanmogne, Georgette D.

In: Current Opinion in Pulmonary Medicine, Vol. 11, No. 3, 05.2005, p. 208-212.

Research output: Contribution to journalReview article

@article{1815d1a02eee4c85898aec82204766d9,
title = "Noninfectious pulmonary complications of HIV/AIDS",
abstract = "Purpose of review: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era. Recent findings: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients. This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients. The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients. Concurrent uge of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma. For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment. Summary: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies. Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer. The full impact of HAART on HIV pulmonary hypertension remains to be determined.",
keywords = "Cancer, Complications, HIV/AIDS, Highly active antiretroviral therapy, Pulmonary pulmonary hypertension",
author = "Kanmogne, {Georgette D.}",
year = "2005",
month = "5",
doi = "10.1097/01.mcp.0000159833.28271.00",
language = "English (US)",
volume = "11",
pages = "208--212",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Noninfectious pulmonary complications of HIV/AIDS

AU - Kanmogne, Georgette D.

PY - 2005/5

Y1 - 2005/5

N2 - Purpose of review: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era. Recent findings: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients. This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients. The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients. Concurrent uge of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma. For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment. Summary: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies. Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer. The full impact of HAART on HIV pulmonary hypertension remains to be determined.

AB - Purpose of review: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era. Recent findings: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients. This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients. The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients. Concurrent uge of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma. For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment. Summary: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies. Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer. The full impact of HAART on HIV pulmonary hypertension remains to be determined.

KW - Cancer

KW - Complications

KW - HIV/AIDS

KW - Highly active antiretroviral therapy

KW - Pulmonary pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=17744365034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744365034&partnerID=8YFLogxK

U2 - 10.1097/01.mcp.0000159833.28271.00

DO - 10.1097/01.mcp.0000159833.28271.00

M3 - Review article

C2 - 15818181

AN - SCOPUS:17744365034

VL - 11

SP - 208

EP - 212

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 3

ER -